Aptevo Therapeutics (APVO) Accumulated Depreciation & Amortization (2016 - 2024)
Aptevo Therapeutics (APVO) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $13.9 million as the latest value for Q4 2024.
- Quarterly Accumulated Depreciation & Amortization rose 2.59% to $13.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $13.9 million through Dec 2024, up 2.59% year-over-year, with the annual reading at $13.9 million for FY2024, 2.59% up from the prior year.
- Accumulated Depreciation & Amortization hit $13.9 million in Q4 2024 for Aptevo Therapeutics, up from $13.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $13.9 million in Q4 2024 to a low of $11.1 million in Q4 2020.
- Historically, Accumulated Depreciation & Amortization has averaged $12.8 million across 5 years, with a median of $13.0 million in 2022.
- Biggest five-year swings in Accumulated Depreciation & Amortization: rose 12.28% in 2020 and later rose 2.59% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $11.1 million in 2020, then grew by 10.19% to $12.3 million in 2021, then increased by 6.08% to $13.0 million in 2022, then grew by 4.35% to $13.6 million in 2023, then rose by 2.59% to $13.9 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for APVO at $13.9 million in Q4 2024, $13.6 million in Q4 2023, and $13.0 million in Q4 2022.